Ra Capital Management, L.P. Acquires 84,124 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 84,124 shares of the stock in a transaction that occurred on Wednesday, July 22nd. The stock was acquired at an average cost of $9.93 per share, for a total transaction of $835,351.32. Following the completion of the acquisition, the director owned 17,182,603 shares in the company, valued at $170,623,247.79. This represents a 0.49% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 24th, Ra Capital Management, L.P. acquired 41,319 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.99 per share, with a total value of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. acquired 59,880 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.96 per share, with a total value of $596,404.80.
• On Tuesday, July 21st, Ra Capital Management, L.P. acquired 120,582 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.55 per share, for a total transaction of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. bought 15,102 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.97 per share, for a total transaction of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. purchased 391,019 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.57 per share, for a total transaction of $3,351,032.83.

Artiva Biotherapeutics Stock Down 5.1%

ARTV opened at $10.00 on Thursday. The firm has a 50-day simple moving average of $8.92 and a two-hundred day simple moving average of $7.45. Artiva Biotherapeutics, Inc. has a 52 week low of $2.22 and a 52 week high of $14.53. The company has a market capitalization of $247.10 million, a PE ratio of -2.82 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, sell-side analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ARTV shares. Wedbush lifted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Needham & Company LLC reissued a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Finally, HC Wainwright upped their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Artiva Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Key Artiva Biotherapeutics News

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: RA Capital Management purchased an additional 41,319 ARTV shares at an average price of $9.99, investing approximately $413,000. This followed purchases of 59,880 shares on July 23, 84,124 shares on July 22, and 120,582 shares on July 21. The four transactions totaled roughly 306,000 shares and $3.0 million, increasing RA Capital’s ownership to more than 17.28 million shares. Continued insider accumulation can signal confidence in Artiva’s outlook and may provide a positive catalyst for the stock. Artiva Biotherapeutics director stock purchase report
• Positive Sentiment: Analyst coverage remains generally constructive. Artiva has an overall “Moderate Buy” rating and an average price target of $39, substantially above recent trading levels. Needham, Wedbush and Cantor Fitzgerald maintain bullish ratings, with Wedbush recently raising its target to $40. These targets reflect potential upside if Artiva’s off-the-shelf natural-killer-cell therapy pipeline advances successfully. Artiva Biotherapeutics analyst ratings
• Neutral Sentiment: Other institutional investors, including Bank of America, Jane Street, Qube Research & Technologies and Bridgeway Capital Management, have initiated or increased positions. However, the reported positions are relatively small and do not represent a major change in institutional ownership.
• Negative Sentiment: Artiva’s financial profile remains a risk. The company’s latest quarterly loss of $0.95 per share was worse than the $0.88 analyst consensus, and analysts expect a full-year loss of approximately $2.45 per share. Wall Street Zen and Weiss Ratings have issued sell-oriented views, underscoring concerns about ongoing cash needs, clinical execution and the absence of commercial revenue.

Institutional Investors Weigh In On Artiva Biotherapeutics

Large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC raised its position in Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after purchasing an additional 644,658 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares during the period. Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics in the 4th quarter worth approximately $341,000. Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $67,000. Finally, Landscape Capital Management L.L.C. bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at approximately $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.